SEARCH

SEARCH BY CITATION

References

  • 1
    Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012;125:1422.
  • 2
    Martins LC, Ferreira-Melo SE, Sabha M, et al.Acute effects of pharmacotherapies in blood pressure in normotensive moderate smokers. Blood Press. 2005;18:255260.
  • 3
    Bamias A, Manios E, Karadimou A, et al.The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. Eur J Cancer. 2011;47:16601668.
  • 4
    Luque-Ramírez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steril. 2009;91:25272536.
  • 5
    Pilecki T, Paczek L, Senatorski G, et al.Effect of immunosuppressive treatment on diurnal profile of blood pressure. Pol Merkur Lekarski.2002;13:3740.
  • 6
    Wasilewska A, Zoch-Zwierz W, Tomaszewska B, Tenderenda E. The effect of cyclosporine A in steroid-dependent nephrotic syndrome in children. Pol Merkur Lekarski.2005;18:168172.
  • 7
    Sudano I, Flammer AJ, Periat D, et al.Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010;122:17891796.
  • 8
    Wright JT, McKenney JM, Lehany AM, et al.The effect of high-dose short-term ibuprofen on antihypertensive control with hydrochlorothiazide. Clin Pharmacol Ther. 1989;46:440444.
  • 9
    Kostka-Jeziorny K, Uruski P, Tykarski A. Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood Press. 2011;20:104110.
  • 10
    Magen E, Viskoper JR, Mishral J, et al.Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertens. 2005;19:667673.
  • 11
    Sumino H, Ichikawa S, Kumakura H, et al.Effects of hormone replacement therapy on office and ambulatory blood pressure in Japanese hypertensive postmenopausal women. Hypertens Res. 2003;26:369376.
  • 12
    Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21:9295.
  • 13
    Gürsoy A, Erdoğan MF, Cin MO, et al.Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension. Endocr Pract. 2005;11:308312.
  • 14
    Satin LZ, Gutstein DE. Meeting report: 5th annual cardiovascular risk assessment summit. Drug Inf J.2011;45:535540.
  • 15
    Turner JR. Cardiovascular safety watch column. J Clin Stud.2011;3:10.
  • 16
    O’Brien E. Why ABPM should be mandatory in all trial of blood pressure-lowering drugs. Drug Inf J.2011;45:233239.
  • 17
    O’Brien E. The value of 24-hour blood pressure monitoring to assess the efficacy of antihypertensive drug treatment. Hot Topics Hypertens.2011;4:723.
  • 18
    Stolarz-Skrzypek K, Thijs L, Wizner B, et al.From pioneering to implementing automated blood pressure measurement in clinical practice: Thomas Pickering’s legacy. Blood Press Monit.2010;15:7281.
  • 19
    Owens P, Atkins N, O’Brien E. Diagnosis of white coat hypertension by ambulatory blood pressure monitoring. Hypertension. 1999;34:267272.
  • 20
    O’Brien E. First Thomas Pickering Memorial Lecture: ambulatory blood pressure measurement is essential for the management of hypertension. J Clin Hypertens (Greenwich).2012; doi: 10.1111/j.1751-7176.2012.00698.
  • 21
    O’Brien E. The circadian nuances of hypertension: a reappraisal of 24-h ambulatory blood pressure measurement in clinical practice. Ir J Med Sci. 2007;176:5563.
  • 22
    O’Brien E. 24-hour ambulatory blood pressure measurement in clinical practice and research: a critical review of a technique in need of implementation. J Int Med. 2011;269:478495.
  • 23
    Yusuf S, Sleight P, Pogue J, et al.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145153.
  • 24
    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145153.
  • 25
    Williams B. The renin-angiotensin system and cardiovascular disease: hope or hype?J Renin Angiotensin Aldosterone Syst.2000;1:142146.
  • 26
    Svensson P, de Faire U, Sleight P, et al.Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001;38:E28E32.
  • 27
    Moutsatsos GD. More hype than HOPE. Hypertension. 2003;41:e4.
  • 28
    Stockbridge S. Letter to the Editor: ABPM part of FDA reviews. Drug Inf J.2011;45:567.
  • 29
    Dolan E, Stanton A, Thijs L, et al.Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. The Dublin Outcome Study. Hypertension. 2005;46:156161.
  • 30
    Sega R, Facchetti R, Bombelli M, et al.Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population. Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:17771783.
  • 31
    Mancia G, Bombelli M, Facchetti R, et al.Long-term prognostic value of blood pressure variability in the general population. Results of the Pressioni Arteriose Monitorate a Loro Associazioni study. Hypertension. 2007;49:12651270.
  • 32
    Ben-Dov IZ, Kark JD, Ben-Ishay D, et al.Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension. 2007;49:12351241.
  • 33
    Fagard RH, Celis H, Thijs L, et al.Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:5561.
  • 34
    Muxfeldt ES, Cardoso CR, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med. 2009;169:874880.
  • 35
    Fan HQ, Li Y, Thijs L, et al.Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens. 2010;28:20362045.
  • 36
    O’Brien E. Is the case for ABPM as a routine investigation in clinical practice not overwhelming?Hypertension. 2007;50:284286.
  • 37
    Logan AG. Ambulatory blood pressure monitoring: it’s time to move on!J Hypertens. 2010;28:20002002.
  • 38
    Rocco MB, Barry J, Campbell S, et al.Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation. 1987;75:395400.
  • 39
    Elliott WJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke. 1998;29:992996.
  • 40
    Kario K. Time for focus on morning hypertension: pitfall of current antihypertensive medication. Am J Hypertens. 2005;18:149151.
  • 41
    Rothwell PM, Howard SC, Dolan E, et al.Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895905.
  • 42
    Rothwell PM, Howard SC, Dolan E, et al.Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol.2010;9:469480.
  • 43
    Dolan E, O’Brien E. Blood pressure variability: clarity for clinical practice. Hypertension. 2010;56:179181.
  • 44
    ICH Guideline E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005.http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf. Accessed June 20, 2012.
  • 45
    ICH Guideline E14 Questions & Answers Document, Revision 1. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: questions & answers. 2012. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Q_As_R1_step4.pdf. Accessed June 20, 2012.
  • 46
    Satin LZ, Durham TA, Turner JR. Assessing a drug’s proarrhythmic liability: an overview of computer simulation modeling, nonclinical assays, and the Thorough QT/QTc Study. Drug Inf J.2011;45:357375.
  • 47
    Turner JR. Integrated cardiovascular safety: employing a three-component risk exclusion model in the assessment of investigational drugs. Appl Clin Trials. 2010;19: June issue:7679.
  • 48
    Highlights of prescribing information for crizotinib. http://labeling.pfizer.com/showlabeling.aspx?id=676. Accessed August 9, 2012.
  • 49
    Highlights of prescribing information for vemurafenib. http://www.gene.com/gene/news/news-events/zelboraf/pi.pdf. Accessed August 9, 2012.
  • 50
    Rock EP, Finkle J, Fingert HJ, et al.Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J. 2009;157:827836, 836.e1.
  • 51
    Levitan BS, Andrews EB, Gilsenan A, et al.Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther. 2011;89:217224.
  • 52
    Noel R, Hermann R, Levitan B, et al.Application of the Benefit-Risk Action Team (BRAT) Framework in Pharmaceutical R&D: results from a pilot program. Drug Inf J.2012; doi:10.1177/0092861512458908.
  • 53
    Krucoff M. Focus on the cardiac safety research consortium. Drug Inf J.2011;45:241244.
  • 54
    Krakoff LR. Cost-effectiveness of ambulatory blood pressure: a reanalysis. Hypertension. 2006;47:2934.
  • 55
    White WB. Expanding the use of ambulatory blood pressure monitoring for the diagnosis and management of patients with hypertension. Hypertension. 2006;47:1415.
  • 56
    O’Brien E. Ambulatory blood pressure measurement. The case for implementation in primary care. Hypertension. 2008;51:14351441.
  • 57
    National Institute for Health and Clinical Excellence (NICE). Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 127. 2011. www.nice.org.uk/guidance/CG127. Accessed August 9, 2012.
  • 58
    Lovibond K, Jowett S, Barton P, et al.Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011;378:12191230.
  • 59
    White WB, Maraka S. Is it possible to manage hypertension and evaluate therapy without ambulatory blood pressure monitoring?Curr Hypertens Rep. 2012;14:366373.
  • 60
    Campbell P, Ghuman N, Wakefield D, et al.Long-term reproducibility of ambulatory blood pressure is superior to office blood pressure in the very elderly. J Hum Hypertens. 2010;24:749754.
  • 61
    White WB. “The nighttime might be the right time” for cardiovascular event prediction. Hypertension. 2012;60:89.
  • 62
    White WB. The risk of waking-up: impact of the morning surge in blood pressure. Hypertension. 2010;55:835837.
  • 63
    O’Brien E, Pickering T, Asmar R, et al.International protocol for validation of blood pressure measuring devices in adults. Blood Press Monit.2002;7:317.
  • 64
    O’Brien E, Atkins N, Stergiou G, et al.European Society of Hypertension International Protocol for the validation of blood pressure measuring devices in adults. 2010 Revision. Blood Press Monit.2010;15:2338.
  • 65
    Stergiou G, Karpettas N, Atkins N, O’Brien E. European Society of Hypertension International Protocol for the validation of blood pressure monitors: a critical review of its application and rationale for revision. Blood Press Monit.2010;15:3948.